[HTML][HTML] Review of malaria situation in Cameroon: technical viewpoint on challenges and prospects for disease elimination

C Antonio-Nkondjio, C Ndo, F Njiokou, JD Bigoga… - Parasites & vectors, 2019 - Springer
Malaria still has a devastating impact on public health and welfare in Cameroon. Despite the
increasing number of studies conducted on disease prevalence, transmission patterns or …

Protozoan persister-like cells and drug treatment failure

MP Barrett, DE Kyle, LD Sibley, JB Radke… - Nature Reviews …, 2019 - nature.com
Antimicrobial treatment failure threatens our ability to control infections. In addition to
antimicrobial resistance, treatment failures are increasingly understood to derive from cells …

[HTML][HTML] Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study

KE Battle, TCD Lucas, M Nguyen, RE Howes… - The Lancet, 2019 - thelancet.com
Background Plasmodium vivax exacts a significant toll on health worldwide, yet few efforts to
date have quantified the extent and temporal trends of its global distribution. Given the …

8-Aminoquinoline therapy for latent malaria

JK Baird - Clinical Microbiology Reviews, 2019 - Am Soc Microbiol
The technical genesis and practice of 8-aminoquinoline therapy of latent malaria offer
singular scientific, clinical, and public health insights. The 8-aminoquinolines brought …

Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent Plasmodium vivax malaria

JK Baird, M Louisa, R Noviyanti, L Ekawati… - JAMA Network …, 2018 - jamanetwork.com
Importance Latent hepaticPlasmodium vivaxhypnozoites provoke repeated clinical attacks
called relapses. Only primaquine phosphate kills hypnozoites, and its therapeutic activity …

Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria

NN Chamma-Siqueira, SC Negreiros… - … England Journal of …, 2022 - Mass Medical Soc
Background In most of the Americas, the recommended treatment to prevent relapse of
Plasmodium vivax malaria is primaquine at a total dose of 3.5 mg per kilogram of body …

[HTML][HTML] Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions

MU Ferreira, TN de Sousa, GW Rangel… - International Journal for …, 2021 - Elsevier
Emerging antimalarial drug resistance may undermine current efforts to control and
eliminate Plasmodium vivax, the most geographically widespread yet neglected human …

[HTML][HTML] The global burden of Plasmodium vivax malaria is obscure and insidious

KE Battle, JK Baird - PLoS Medicine, 2021 - journals.plos.org
The global burden of Plasmodium vivax malaria is obscure and insidious | PLOS Medicine Skip
to main content Advertisement PLOS Medicine Browse Current Issue Journal Archive Special …

[HTML][HTML] Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study

N Nekkab, R Lana, M Lacerda, T Obadia… - PLoS …, 2021 - journals.plos.org
Background Despite recent intensification of control measures, Plasmodium vivax poses a
major challenge for malaria elimination efforts. Liver-stage hypnozoite parasites that cause …

[HTML][HTML] Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria

J Watson, WRJ Taylor, G Bancone… - PLoS neglected …, 2018 - journals.plos.org
Background The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of
vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in …